Quantum BioPharma is trading 5.71% higher at $4.10, with sector-related strength reported in premarket trading.
- A September 24 announcement said licensee Unbuzzd Wellness appointed Michael Zapolin as CEO.
- Unbuzzd Wellness has plans for financing, a stock listing and U.S. commercialization. The release did not explicitly link the announcement to Quantum BioPharma’s share move, while broader sector signals were mixed.